ArticleBlood advances2023

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Raphael E Steiner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.